Patent ID: 11896382
Assignee: RETISPEC INC.
Field: Measurement (Instruments)
Classification: CPC A  G | IPC A  G

Claim 21:
22. A method of non-invasive in vivo detection of one or more Alzheimer's Disease (AD)-associated pathologies from an eye of a subject, comprising:
controlling a spectral reflectance imaging unit to illuminate a fundus of the eye using a light source;
detecting light from the eye resulting from the light source using a light sensor for determining spectral reflectance information;
determining, using one or more processors utilizing a first neural network, a location of one or more region of interest (ROI) from the spectral reflectance information as being a potential AD-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy;
illuminating the fundus of the eye only in each of the one or more ROI, and detecting light from the one or more ROI for determining imaging information; and
classifying, with one or more processors utilizing a second neural network and using at least the imaging information, the subject as having one or more AD-associated pathologies, the one or more AD-associated pathologies associated with the one or more biomarkers indicative of Tauopathy, wherein the one or more biomarkers indicative of Tauopathy comprise Tau neurofibrillary tangles.